Connection

Charles Bennett to Neutropenia

This is a "connection" page, showing publications Charles Bennett has written about Neutropenia.
Connection Strength

4.183
  1. Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist. 2019 04; 24(4):537-548.
    View in: PubMed
    Score: 0.607
  2. Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis. J Natl Cancer Inst. 2013 Aug 07; 105(15):1072-3.
    View in: PubMed
    Score: 0.411
  3. Colony-stimulating factors for febrile neutropenia. N Engl J Med. 2013 07 18; 369(3):286.
    View in: PubMed
    Score: 0.411
  4. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med. 2013 Mar 21; 368(12):1131-9.
    View in: PubMed
    Score: 0.402
  5. Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care. Oncologist. 2007 Aug; 12(8):1019-26.
    View in: PubMed
    Score: 0.272
  6. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant. 2007 Aug; 40(3):185-92.
    View in: PubMed
    Score: 0.269
  7. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist. 2007 Apr; 12(4):478-83.
    View in: PubMed
    Score: 0.266
  8. Systematic review of piperacillin-induced neutropenia. Drug Saf. 2007; 30(4):295-306.
    View in: PubMed
    Score: 0.261
  9. When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective? J Clin Oncol. 2006 Jul 01; 24(19):2975-7.
    View in: PubMed
    Score: 0.250
  10. Acting on imperfect evidence: How much regret are we ready to accept? J Clin Oncol. 2005 Oct 01; 23(28):6822-5.
    View in: PubMed
    Score: 0.238
  11. Granulocyte colony--stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer : the 40% rule revisited. Pharmacoeconomics. 2005; 23(8):767-75.
    View in: PubMed
    Score: 0.227
  12. Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials. Med Pediatr Oncol. 2000 Feb; 34(2):92-6.
    View in: PubMed
    Score: 0.162
  13. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med. 1992 Feb 01; 116(3):177-82.
    View in: PubMed
    Score: 0.093
  14. Myeloid growth factors. J Natl Compr Canc Netw. 2009 Jan; 7(1):64-83.
    View in: PubMed
    Score: 0.075
  15. Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Feb; 5(2):188-202.
    View in: PubMed
    Score: 0.066
  16. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006 Jul 01; 24(19):3187-205.
    View in: PubMed
    Score: 0.062
  17. Cost analyses of granulocyte colony stimulating factor: a focus on older patients with cancer. Crit Rev Oncol Hematol. 2003 Oct 15; 48(Suppl):S71-4.
    View in: PubMed
    Score: 0.052
  18. Cost analyses of adjunct colony stimulating factors for older patients with acute myeloid leukaemia : can they improve clinical decision making? Drugs Aging. 2003; 20(7):479-83.
    View in: PubMed
    Score: 0.049
  19. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 2000 Oct 15; 18(20):3558-85.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.